SETTING UP NEW VENTURES AS PORTFOLIO COMPANIES
While evaluating new technology projects, we frequently identify high-value opportunities i.e. early stage projects based on breakthrough science with a high commercialization potential. To ensure appropriate development of these ideas to promising commercialization projects, we often engage our organization as an active shareholder and partner in the new venture offering our management skills and extensive international network for the benefit of the venture. During this process, we will assume key executive positions within the new company (e.g. CEO, Chairman) working together with the technology originators towards venture capital funding, deal making, further development of the technology and/or exit.
Below, you will find additional information on our current Portfolio Companies founded/co-founded by one or more partners as well as information on our exited ventures.
Neuroscience Technologies SLP is a biomedical company with expertise in human pain neurophysiology. It offers services to the pharmaceutical and biotechnology industries for assessing new pain therapies and neurotoxicity via the use of a proprietary microneurography platform. This platform is capable of quantifying spontaneous activity in pain fibers, both in patients and in human and laboratory models of painful conditions. The company offers preclinical and clinical capabilities at both its Barcelona and London sites.
APIM Therapeutics AS is a venture capital financed Norwegian biotechnology company developing novel peptide drugs for various oncology indications. Targeting a novel therapeutic intervention point, the company’s current lead, ATX-101, sensitizes cancer cells to the action of 29 different anti-cancer drugs across multiple indications. ATX-101 has shown proof-of-concept in multiple preclinical in vivo and ex vivo cancer models of solid tumors and blood cancer (e.g. bladder, prostate, multiple myeloma, leukemia) in combination with >5 clinical drugs. Having concluded GLP toxicology studies, the company will be submitting two clinical trial applications to regulatory authorities in Q4 2015. Two phase I/IIa clinical trials in advanced cancer (intravenous administration) and non-muscle invasive bladder cancer (intravesical administration) are planned for 2016.
Avexxin is a pharmaceutical company aimed at the discovery and development of small molecule therapies against chronic inflammatory diseases with clinical Proof-of-Concept in its lead indication of psoriasis. Avexxin has several other compounds in preclinical development. Whilst individually unique, Avexxin's discovery and development programs all share a key common characteristic: they all selectively target the intracellular enzyme Group IVa cPLA2a, a validated pro-inflammatory target and its downstream effector NF-κB in multiple disease indications. Based on current data, Avexxin’s approach to treating chronic inflammation represents a new and broadly applicable therapeutic paradigm with less adverse effects compared to today’s treatments, yet the same efficiency as today's widely used therapeutics.
Orbit Genomics, Inc. is dedicated to developing diagnostics and services based on microsatellite markers. The company’s first products will improve brain cancer diagnosis by eliminating unnecessary brain biopsies through the use of a non-invasive, blood based biopsy based on the microsatellite fingerprint. Microsatellites, or short tandem repeats, are the standard for forensics and paternity testing, however their use has not extended to disease diagnosis. Current genome sequencing focuses on single base mutations and is sub-optimal for microsatellites. Orbit Genomics has developed proprietary algorithms to optimize microsatellite sequencing and has identified markers specific to several diseases by analyzing thousands of genomes. The company is currently seeking investors to fund the development of the commercial platform which will serve as a basis for not only brain cancer, but also companion diagnostics and other products in the pipeline.
Idogen AB is a publicly traded company listed on AktieTorget in Stockholm. Idogen is developing the first therapeutic vaccine based on autologous tolerogenic dendritic cells and is founded by Ventac Partners together with scientists from the Biomedical Centre at Lund University, Sweden. The first indication under development is treatment of anti-drug antibodies in haemophilia A. The concept is also expected to have significant applications in the treatment of autoimmune diseases as well as the prevention of rejection of transplanted cells and organs.
Miacom is a German/US molecular diagnostic company offering unique and innovative solutions for the rapid identification and characterization of microorganisms for a variety of infectious diseases. Miacom currently offers molecular diagnostic tests for pneumonia and sepsis including multiplex panels enabling identification of up to 14 clinically relevant pathogens directly from respiratory secretions or positive blood cultures within 30 minutes.
Regenesance is a 2009 spin-out of the Academic Medical Center in Amsterdam, the Netherlands (AMC). The company was formed to develop new drug products that block complement system factor C6 activity. In collaboration with the AMC, Regenesance found that inhibiting C6 can prevent unwanted cell lysis in animal models: a hallmark of several life-threatening diseases in patients. The company’s current lead candidate Regenemab™ is a humanized antibody undergoing late non-clinical phase testing as a potential treatment for orphan diseases such as paroxysmal nocturnal hemoglobinurea (PNH), amyotrophic lateral sclerosis (ALS) and myasthenia gravis.
RhoVac ApS is a Danish biotech company focusing on discovery and development of highly potent therapeutic cancer vaccines targeting RhoC, a protein expressed at high levels in cancer cells having metastatic potential. Based on the pivotal role of RhoC in multiple tumors, RhoVac’s lead compound RV001, currently in late preclinical development, is expected to have significant therapeutic potential in a broad variety of cancer indications.
Zestagen is a Swiss biotechnology company developing light chain monoclonal antibodies against Extracellular Heat Shock Protein-90 (ehsp90). Unlike hsp90 which performs both housekeeping and cancer-related functions (and is a validated pharmaceutical target), ehsp90 offers a superior therapeutic profile as it is specific to cancer cells only. As such, ehp90 has been implicated in several cancer promoting roles including stimulation of cancer cell motility, migration and metastasis. Zestagen's mAbs bind ehsp90 at the surface of cancer cells (but not normal cells) leading to significant inhibition of metastasis in preclinical cancer animal models. These properties offer promising development opportunities for indications such as triple negative breast cancer, melanoma and non-small cell lung cancer.
Boulder Diagnostics Inc. is an in vitro diagnostics company that focuses on identifying, developing, and marketing new diagnostic technologies for underserved markets. Flagship company products include Spirofind®, an assay to assist in the diagnosis of Lyme disease, Goutifind™, an assay useful for the diagnosis of Gout and Stratokine™, an assay to help select biologics for autoimmune disease based on monitoring and prognosis of drug response. The company was sold to Oxford Immune in July 2014.
Listed in 2007 on the Nasdac OMX stock exchange in Copenhagen, Exiqon operates in two business areas: life sciences and diagnostics.
Exiqon Life Sciences, a leading provider of flexible solutions for RNA analysis. Exiqon’s research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases.
Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions based on the tools developed by Exiqon Life Sciences.
Sold to F. Hoffmann-La Roche in 2014 for USD 450 million, Santaris Pharma A/S has become Roche Innovation Center Copenhagen A/S and engages in developing RNA-targeted drugs. The company through its locked nucleic acid platform engages in the discovery of medicines across various therapeutic areas. The company operates as a subsidiary of F. Hoffmann-La Roche Ltd.
For more information on our portfolio companies, feel free to contact us directly.